Factor D Inhibitor Wins Approval for PNH With Extravascular Hemolysis
(MedPage Today) -- The FDA approved the oral factor D inhibitor danicopan (Voydeya) as an add-on therapy to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH), AstraZeneca announced.
The approval specifies use...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news